Tumour Imaging

2020 ◽  
pp. 205-225
Author(s):  
D. A. Scullion ◽  
G. Cook ◽  
R. Allan ◽  
D. A. Cunningham
Keyword(s):  
Tumour Imaging

Human Fibronectin Extra-Domain B (EDB)-Specific Aptide (APTEDB) Radiolabelling with Technetium-99m as a Potent Targeted Tumour-Imaging Agent

2018 ◽  
Vol 18 (2) ◽  
pp. 277-285 ◽  
Author(s):  
Mohsen Mohammadgholi ◽  
Nourollah Sadeghzadeh ◽  
Mostafa Erfani ◽  
Saeid Abediankenari ◽  
Seyed Mohammad Abedi ◽  
...  
Keyword(s):  
Radioligand Binding ◽  
Specific Binding ◽  
Specific Protein ◽  
Tumour Imaging ◽  
Specific Binding Ratio ◽  
Tumour Uptake ◽  
Technetium 99M ◽  
In Vivo Experiments ◽  
Human Fibronectin

Background: Human fibronectin extra-domain B (EDB) is particularly expressed during angiogenesis progression. It is, thus, a promising marker of tumour growth. Aptides are a novel class of peptides with high-affinity binding to specific protein targets. APTEDB is an antagonist-like ligand that especially interacts with human fibronectin EDB. Objective: This study was the first attempt in which the hydrazinonicotinamide (HYNIC)-conjugated APTEDB was labelled with technetium-99m (99mTc) as an appropriate radiotracer and tricine/EDDA exchange labeling. Methods: Radiochemical purity, normal saline, and serum stability were evaluated by HPLC and radio-isotope TLC scanner. Other examinations, such as protein-binding calculation, dissociation radioligand binding assay, and partition coefficient constant determination, were also carried out. The cellular-specific binding of 99mTc- HYNIC-conjugated APTEDB was assessed in two EDB-positive (U87MG) and EDB-negative (U373MG) cell lines. Bio-distribution was investigated in normal mice as well as in U87MG and U373MG tumour-bearing mice. Eventually, the radiolabelled APTEDB was used for tumour imaging using planar SPECT. Results: Radiolabelling was achieved with high purity (up to 97%) and accompanied by high solution (over 90% after overnight) and serum (80% after 2 hours) stability. The obtained cellular-specific binding ratio was greater than nine-fold. In-vivo experiments showed rapid blood clearance with mainly renal excretion and tumour uptake specificity (0.48±0.03% ID/g after 1h). The results of the imaging also confirmed considerable tumour uptake for EDB-positive cell line compared with the EDB-negative one. Conclusion: Aptides are considered to be a potent candidate for biopharmaceutical applications. They can be modified with imaging or therapeutic agents. This report shows the capability of 99mTc-HYNIC-APTEDB for human EDB-expressing tumours detection.

scholarly journals In vivo tumour imaging employing regional delivery of novel gallium radiolabelled polymer composites

2021 ◽  
Vol 25 (1) ◽  
Author(s):  
Ross W. Stephens ◽  
Gregory D. Tredwell ◽  
Jessica L. Bell ◽  
Karen J. Knox ◽  
Lee A. Philip ◽  
...  
Keyword(s):  
Normal Liver ◽  
Ct Imaging ◽  
Liver Imaging ◽  
Polymer Microspheres ◽  
Tumour Imaging ◽  
Planar Imaging ◽  
Rabbit Lung ◽  
Vitro Binding

Abstract Background Understanding the regional vascular delivery of particles to tumour sites is a prerequisite for developing new diagnostic and therapeutic composites for treatment of oncology patients. We describe a novel imageable 67Ga-radiolabelled polymer composite that is biocompatible in an animal tumour model and can be used for preclinical imaging investigations of the transit of different sized particles through arterial networks of normal and tumour-bearing organs. Results Radiolabelling of polymer microspheres with 67Ga was achieved using a simple mix and wash method, with tannic acid as an immobilising agent. Final in vitro binding yields after autoclaving averaged 94.7%. In vivo stability of the composite was demonstrated in New Zealand white rabbits by intravenous administration, and intrahepatic artery instillations were made in normal and VX2 tumour implanted rabbit livers. Stability of radiolabel was sufficient for rabbit lung and liver imaging over at least 3 hours and 1 hour respectively, with lung retention of radiolabel over 91%, and retention in both normal and VX2 implanted livers of over 95%. SPECT-CT imaging of anaesthetised animals and planar imaging of excised livers showed visible accumulation of radiolabel in tumours. Importantly, microsphere administration and complete liver dispersal was more easily achieved with 8 μm diameter MS than with 30 μm MS, and the smaller microspheres provided more distinct and localised tumour imaging. Conclusion This method of producing 67Ga-radiolabelled polymer microspheres is suitable for SPECT-CT imaging of the regional vascular delivery of microspheres to tumour sites in animal models. Sharper distinction of model tumours from normal liver was obtained with smaller MS, and tumour resolution may be further improved by the use of 68Ga instead of 67Ga, to enable PET imaging.

Radioiodinated peanut lectin: Clinical use as a tumour-imaging agent and potential use in assessing renal-tubular function

1986 ◽  
Vol 11 (9) ◽  
pp. 350-354 ◽  
Author(s):  
E. A. Abdi ◽  
V. J. Kamitomo ◽  
T. A. McPherson ◽  
Z. Catz ◽  
G. Boniface ◽  
...  
Keyword(s):  
Tubular Function ◽  
Imaging Agent ◽  
Clinical Use ◽  
Tumour Imaging ◽  
Peanut Lectin ◽  
Renal Tubular Function ◽  
Renal Tubular ◽  
Potential Use

The optimum time for tumour imaging with thallium-201

1988 ◽  
Vol 13 (10) ◽  
Author(s):  
A. Sehweil ◽  
J.H. McKillop ◽  
G. Ziada ◽  
M. Al-Sayed ◽  
H. Abdel-Dayem ◽  
...  
Keyword(s):  
Thallium 201 ◽  
Tumour Imaging ◽  
Optimum Time

TUMOUR IMAGING USING AN IMPROVED METHOD OF DTPA-COUPLED MONOCLONAL ANTIBODIES RADIOLABELLED WITH METALLIC RADIONUCLIDES

The Lancet ◽  
1984 ◽  
Vol 324 (8395) ◽  
pp. 169 ◽  
Author(s):  
A.A. Epenetos ◽  
D. Snook ◽  
G. Hooker ◽  
J.P. Lavender ◽  
K.E. Halnan
Keyword(s):  
Monoclonal Antibodies ◽  
Tumour Imaging ◽  
Improved Method

Synthesis and Binding Affinity of Fluorine Containing NG-acyl and -sulfonyl BIBP3226 Derivatives: Ligands for the NPY Y1 Receptor

2016 ◽  
Vol 69 (7) ◽  
pp. 746
Author(s):  
Nigel A. Lengkeek ◽  
Maxine P. Roberts ◽  
Lei Zhang ◽  
I-Chieh J. Lee ◽  
Christopher J. R. Fookes ◽  
...  
Keyword(s):  
Binding Affinity ◽  
Emission Tomography ◽  
Tumour Imaging ◽  
Y1 Receptor ◽  
Important Amino Acid ◽  
Positron Emission ◽  
Npy Receptor ◽  
Almost All ◽  
Derivatives Of ◽  
Pet Radiopharmaceuticals

The neuropeptide Y (NPY) receptors are abundant in a range of tumours hence are a molecular target for tumour imaging and therapy, particularly by the use of radiolabelled molecules. NG-Substituted derivatives of the NPY receptor antagonist, BIBP3226, were prepared aiming to improve its current usability and to incorporate a positron-emitting radioisotope for development in positron emission tomography (PET) radiopharmaceuticals. The BIBP3226 derivatives were prepared in seven steps while retaining the critically important amino acid chirality. The acyl derivative retained acceptable ligand binding, however the sulfonyl derivatives lost almost all binding affinity.

68Ga-labelled NOTA-RGD-GE11 peptide for dual integrin and EGFR-targeted tumour imaging

2019 ◽  
Vol 68-69 ◽  
pp. 22-30 ◽  
Author(s):  
Chien-Jen Chen ◽  
Chen-Hsin Chan ◽  
Kun-Liang Lin ◽  
Jyun-Hong Chen ◽  
Chun-Hao Tseng ◽  
...  
Keyword(s):  
Tumour Imaging

scholarly journals Renal angiomyoadenomatous tumour: Imaging features

2013 ◽  
Vol 6 (4) ◽  
pp. 140 ◽  
Author(s):  
V. Anik Sahni ◽  
Michelle S. Hirsch ◽  
Stuart G. Silverman
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Imaging Features ◽  
Renal Neoplasms ◽  
Tumour Imaging ◽  
Resonance Imaging ◽  
Imaging Appearance ◽  
Histological Appearance

Renal angiomyoadenomatous tumour is a rare, recently describedneoplasm with a distinctive histological appearance. Althoughreported in the pathology literature, to our knowledge, no priorreports have described its imaging appearance. We describe thecomputed tomography and magnetic resonance imaging featuresof an incidentally detected renal angiomyoadenomatous tumourthat appeared as a well-marginated, solid T2-hypointense enhancing mass, in a 50-year-old woman. It is indistinguishable from a variety of benign and malignant renal neoplasms.

scholarly journals Clinical Translational Evaluation of Al18F-NOTA-FAPI for Fibroblast Activation Protein Targeted Tumour Imaging

2021 ◽  
Author(s):  
Shuailiang Wang ◽  
Xin Zhou ◽  
Xiaoxia Xu ◽  
Jin Ding ◽  
Song Liu ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Fibroblast Activation Protein ◽  
Ct Imaging ◽  
Whole Body ◽  
Tumour Imaging ◽  
Tumour Detection ◽  
Fibroblast Activation ◽  
Tumour Bearing ◽  
Pet Ct ◽  
18F Fdg

Abstract PurposeIn this study, a novel Al18F-NOTA-FAPI probe was developed for fibroblast activation protein (FAP) targeted tumour imaging, which was available to achieve curie level radioactivity by automatic synthesizer. The tumour detection efficacy of Al18F-NOTA-FAPI was further validated both in preclinical and clinical translational studies. MethodsThe radiolabeling procedure of Al18F-NOTA-FAPI was optimized. Cell uptake and competitive binding assay were completed with U87MG and A549 cell lines, to evaluate the affinity and specificity of Al18F-NOTA-FAPI probe. The biodistribution, pharmacokinetics, radiation dosimetry and tumour imaging efficacy of Al18F-NOTA-FAPI probe were researched with healthy Kunming (KM) and/or U87MG model mice. After the approval of ethical committee, Al18F-NOTA-FAPI probe was translated into clinical for the PET/CT imaging of first 10 cancer patients. ResultsThe radiolabeling yield of Al18F-NOTA-FAPI was 33.8 ± 3.2% through manually operation (n = 10), with the radiochemical purity over than 99% and the specific activity of 9.3-55.5 MBq/nmol. Whole body effective dose of Al18F-NOTA-FAPI was estimated to be 1.24E-02 mSv/MBq, lower than several other FAPI probes ( 68Ga-FAPI-04, 68Ga-FAPI-46 and 68Ga-FAPI-74). In U87MG tumour bearing mice, Al18F-NOTA-FAPI showed good tumor detection efficacy from the results of micro PET/CT imaging and biodistribution studies. In organ biodistribution study of human patients, Al18F-NOTA-FAPI showed lower SUVmean than 2-[18F]FDG in most organs, especially in liver (1.1 ± 0.2 vs. 2.0 ± 0.9), brain (0.1 ± 0.0 vs. 5.9 ± 1.3), and bone marrow (0.9 ± 0.1 vs. 1.7 ± 0.4). Meanwhile, Al18F-NOTA-FAPI do not show extensive bone uptakes, and was able to find out more tumour lesions than 2-[18F]FDG in the PET/CT imaging of several patients. ConclusionAl18F-NOTA-FAPI probe was successfully fabricated and applied in fibroblast activation protein targeted tumour PET/CT imaging, which showed excellent imaging quality and tumour detection efficacy in U87MG tumour bearing mice as well as in human cancer patients.

Sign in / Sign up

Export Citation Format

Share Document